"use strict";(globalThis.webpackChunkcerebral_palsy_knowledge_base=globalThis.webpackChunkcerebral_palsy_knowledge_base||[]).push([[2459],{5002:(e,i,s)=>{s.r(i),s.d(i,{assets:()=>c,contentTitle:()=>d,default:()=>p,frontMatter:()=>a,metadata:()=>n,toc:()=>o});const n=JSON.parse('{"id":"management/epilepsy","title":"Epilepsy & Seizure Management","description":"Epilepsy is one of the most common co-occurring conditions in cerebral palsy, affecting about half of all individuals. Understanding seizure risks and management is essential for comprehensive care.","source":"@site/docs/management/epilepsy.md","sourceDirName":"management","slug":"/management/epilepsy","permalink":"/cerebral-palsy-knowledge-base/docs/management/epilepsy","draft":false,"unlisted":false,"tags":[],"version":"current","lastUpdatedAt":1764507312000,"sidebarPosition":9,"frontMatter":{"sidebar_position":9,"title":"Epilepsy & Seizure Management"},"sidebar":"mainSidebar","previous":{"title":"Physical Therapy & Exercise","permalink":"/cerebral-palsy-knowledge-base/docs/management/physical-therapy"},"next":{"title":"Orthopedics & Hip Management","permalink":"/cerebral-palsy-knowledge-base/docs/management/orthopedics"}}');var r=s(4848),t=s(8453),l=s(8609);const a={sidebar_position:9,title:"Epilepsy & Seizure Management"},d="Epilepsy & Seizure Management in Cerebral Palsy",c={},o=[{value:"Prevalence",id:"prevalence",level:2},{value:"Risk Factors by Cerebral Palsy Subtype",id:"risk-factors-by-cerebral-palsy-subtype",level:2},{value:"Other Risk Factors",id:"other-risk-factors",level:3},{value:"Drug-Resistant Epilepsy",id:"drug-resistant-epilepsy",level:2},{value:"Medication Withdrawal Considerations",id:"medication-withdrawal-considerations",level:2},{value:"Management Approach",id:"management-approach",level:2},{value:"Initial Evaluation",id:"initial-evaluation",level:3},{value:"Medication Selection",id:"medication-selection",level:3},{value:"Specialist Team",id:"specialist-team",level:3},{value:"Safety Considerations",id:"safety-considerations",level:2},{value:"Key Points",id:"key-points",level:2},{value:"Related Pages",id:"related-pages",level:2}];function h(e){const i={a:"a",h1:"h1",h2:"h2",h3:"h3",header:"header",hr:"hr",li:"li",ol:"ol",p:"p",strong:"strong",table:"table",tbody:"tbody",td:"td",th:"th",thead:"thead",tr:"tr",ul:"ul",...(0,t.R)(),...e.components};return(0,r.jsxs)(r.Fragment,{children:[(0,r.jsx)(i.header,{children:(0,r.jsx)(i.h1,{id:"epilepsy--seizure-management-in-cerebral-palsy",children:"Epilepsy & Seizure Management in Cerebral Palsy"})}),"\n",(0,r.jsx)(i.p,{children:"Epilepsy is one of the most common co-occurring conditions in cerebral palsy, affecting about half of all individuals. Understanding seizure risks and management is essential for comprehensive care."}),"\n",(0,r.jsx)(i.h2,{id:"prevalence",children:"Prevalence"}),"\n",(0,r.jsxs)(i.table,{children:[(0,r.jsx)(i.thead,{children:(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.th,{children:"Finding"}),(0,r.jsx)(i.th,{children:"Statistic"}),(0,r.jsx)(i.th,{children:"Source"})]})}),(0,r.jsxs)(i.tbody,{children:[(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:"Epilepsy in adults with cerebral palsy/intellectual disability"}),(0,r.jsx)(i.td,{children:"55.6%"}),(0,r.jsx)(i.td,{children:(0,r.jsx)(l.A,{slug:"pubmed-37769423"})})]}),(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:"Epilepsy in large cerebral palsy population (N=88,138)"}),(0,r.jsx)(i.td,{children:"51%"}),(0,r.jsx)(i.td,{children:(0,r.jsx)(l.A,{slug:"pubmed-39596993"})})]}),(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:"Drug-resistant epilepsy"}),(0,r.jsx)(i.td,{children:"22.4%"}),(0,r.jsx)(i.td,{children:(0,r.jsx)(l.A,{slug:"pubmed-37769423"})})]}),(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:"Seizure recurrence after medication withdrawal"}),(0,r.jsx)(i.td,{children:"42.3%"}),(0,r.jsx)(i.td,{children:(0,r.jsx)(l.A,{slug:"pubmed-37769423"})})]})]})]}),"\n",(0,r.jsxs)(i.p,{children:[(0,r.jsx)(i.strong,{children:"Nearly 1 in 2 people with cerebral palsy has epilepsy."})," ",(0,r.jsx)(l.A,{slug:"pubmed-39596993"})]}),"\n",(0,r.jsx)(i.h2,{id:"risk-factors-by-cerebral-palsy-subtype",children:"Risk Factors by Cerebral Palsy Subtype"}),"\n",(0,r.jsxs)(i.p,{children:["A large-scale population study of 88,138 patients found that specific cerebral palsy subtypes carry different epilepsy risks: ",(0,r.jsx)(l.A,{slug:"pubmed-39596993"})]}),"\n",(0,r.jsxs)(i.table,{children:[(0,r.jsx)(i.thead,{children:(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.th,{children:"Subtype"}),(0,r.jsx)(i.th,{children:"Epilepsy Risk"})]})}),(0,r.jsxs)(i.tbody,{children:[(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:(0,r.jsx)(i.strong,{children:"Spastic diplegic"})}),(0,r.jsx)(i.td,{children:"Highest risk (OR = 1.88)"})]}),(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:(0,r.jsx)(i.strong,{children:"Spastic quadriplegic"})}),(0,r.jsx)(i.td,{children:"Elevated risk"})]}),(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:(0,r.jsx)(i.strong,{children:"Dyskinetic"})}),(0,r.jsx)(i.td,{children:"Elevated risk"})]}),(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:(0,r.jsx)(i.strong,{children:"Hemiplegic"})}),(0,r.jsx)(i.td,{children:"Moderate risk"})]}),(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:(0,r.jsx)(i.strong,{children:"Ataxic"})}),(0,r.jsx)(i.td,{children:"Lower risk"})]})]})]}),"\n",(0,r.jsxs)(i.p,{children:[(0,r.jsx)(i.strong,{children:'"Spastic diplegic cerebral palsy demonstrated the strongest correlation with seizure disorders."'})," ",(0,r.jsx)(l.A,{slug:"pubmed-39596993"})]}),"\n",(0,r.jsx)(i.h3,{id:"other-risk-factors",children:"Other Risk Factors"}),"\n",(0,r.jsxs)(i.ul,{children:["\n",(0,r.jsxs)(i.li,{children:["Perinatal infection (OR = 1.61) ",(0,r.jsx)(l.A,{slug:"pubmed-39596993"})]}),"\n",(0,r.jsxs)(i.li,{children:["Abnormal brain imaging ",(0,r.jsx)(l.A,{slug:"pubmed-37769423"})]}),"\n",(0,r.jsxs)(i.li,{children:["More severe intellectual disability ",(0,r.jsx)(l.A,{slug:"pubmed-37769423"})]}),"\n",(0,r.jsxs)(i.li,{children:["More severe neurological involvement ",(0,r.jsx)(l.A,{slug:"pubmed-37769423"})]}),"\n"]}),"\n",(0,r.jsx)(i.h2,{id:"drug-resistant-epilepsy",children:"Drug-Resistant Epilepsy"}),"\n",(0,r.jsxs)(i.p,{children:[(0,r.jsx)(i.strong,{children:"22.4% of individuals with epilepsy and cerebral palsy have drug-resistant epilepsy"}),"\u2014meaning seizures are not controlled despite trying multiple medications. ",(0,r.jsx)(l.A,{slug:"pubmed-37769423"})]}),"\n",(0,r.jsx)(i.p,{children:"Implications:"}),"\n",(0,r.jsxs)(i.ul,{children:["\n",(0,r.jsx)(i.li,{children:"May need specialist epilepsy center evaluation"}),"\n",(0,r.jsx)(i.li,{children:"Consider alternative treatments (vagus nerve stimulation, surgery evaluation)"}),"\n",(0,r.jsx)(i.li,{children:"Focus on seizure safety and quality of life"}),"\n",(0,r.jsx)(i.li,{children:"Higher care burden for caregivers"}),"\n"]}),"\n",(0,r.jsx)(i.h2,{id:"medication-withdrawal-considerations",children:"Medication Withdrawal Considerations"}),"\n",(0,r.jsx)(i.p,{children:"Attempting to stop seizure medications carries significant risk:"}),"\n",(0,r.jsxs)(i.p,{children:[(0,r.jsx)(i.strong,{children:'"42.3% of the individuals who attempted antiseizure medication withdrawal experienced recurrence."'})," ",(0,r.jsx)(l.A,{slug:"pubmed-37769423"})]}),"\n",(0,r.jsx)(i.p,{children:"Key findings:"}),"\n",(0,r.jsxs)(i.ul,{children:["\n",(0,r.jsx)(i.li,{children:"Nearly half experience seizure recurrence when attempting withdrawal"}),"\n",(0,r.jsxs)(i.li,{children:["EEG findings predict relapse risk ",(0,r.jsx)(l.A,{slug:"pubmed-37769423"})]}),"\n",(0,r.jsx)(i.li,{children:"Decisions should involve neurologist experienced with cerebral palsy"}),"\n",(0,r.jsx)(i.li,{children:"Benefits of stopping (reduced side effects) must be weighed against recurrence risk"}),"\n"]}),"\n",(0,r.jsx)(i.h2,{id:"management-approach",children:"Management Approach"}),"\n",(0,r.jsx)(i.h3,{id:"initial-evaluation",children:"Initial Evaluation"}),"\n",(0,r.jsxs)(i.ol,{children:["\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:"Confirm epilepsy diagnosis"})," - Not all movements in cerebral palsy are seizures"]}),"\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:"EEG monitoring"})," - Helps characterize seizure type"]}),"\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:"Brain imaging"})," - MRI to assess structural causes"]}),"\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:"Review of all medications"})," - Interactions with cerebral palsy treatments"]}),"\n"]}),"\n",(0,r.jsx)(i.h3,{id:"medication-selection",children:"Medication Selection"}),"\n",(0,r.jsx)(i.p,{children:"Considerations specific to cerebral palsy:"}),"\n",(0,r.jsxs)(i.ul,{children:["\n",(0,r.jsx)(i.li,{children:"Avoid medications that worsen spasticity (some may help it)"}),"\n",(0,r.jsx)(i.li,{children:"Consider sedation effects in those with cognitive impairment"}),"\n",(0,r.jsx)(i.li,{children:"Watch for bone density effects (many anticonvulsants reduce bone density)"}),"\n",(0,r.jsx)(i.li,{children:"Account for swallowing difficulties (liquid vs. tablet formulations)"}),"\n",(0,r.jsx)(i.li,{children:"Interactions with baclofen, botulinum toxin, and other cerebral palsy medications"}),"\n"]}),"\n",(0,r.jsx)(i.h3,{id:"specialist-team",children:"Specialist Team"}),"\n",(0,r.jsxs)(i.table,{children:[(0,r.jsx)(i.thead,{children:(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.th,{children:"Specialist"}),(0,r.jsx)(i.th,{children:"Role"})]})}),(0,r.jsxs)(i.tbody,{children:[(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:(0,r.jsx)(i.strong,{children:"Neurologist"})}),(0,r.jsx)(i.td,{children:"Primary seizure management"})]}),(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:(0,r.jsx)(i.strong,{children:"Physiatrist"})}),(0,r.jsx)(i.td,{children:"Coordinate with spasticity treatment"})]}),(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:(0,r.jsx)(i.strong,{children:"Epileptologist"})}),(0,r.jsx)(i.td,{children:"Drug-resistant cases"})]}),(0,r.jsxs)(i.tr,{children:[(0,r.jsx)(i.td,{children:(0,r.jsx)(i.strong,{children:"Pharmacist"})}),(0,r.jsx)(i.td,{children:"Medication interactions"})]})]})]}),"\n",(0,r.jsx)(i.h2,{id:"safety-considerations",children:"Safety Considerations"}),"\n",(0,r.jsx)(i.p,{children:"For adults with cerebral palsy and epilepsy:"}),"\n",(0,r.jsxs)(i.ul,{children:["\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:"Supervision during bathing"})," - Drowning risk with seizures"]}),"\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:"Fall prevention"})," - Combined mobility issues and seizure risk"]}),"\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:"Medication adherence support"})," - Especially if cognitive impairment"]}),"\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:"Caregiver seizure training"})," - Recognition and response"]}),"\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:"Emergency medication access"})," - Rescue medications if prescribed"]}),"\n"]}),"\n",(0,r.jsx)(i.h2,{id:"key-points",children:"Key Points"}),"\n",(0,r.jsxs)(i.ul,{children:["\n",(0,r.jsxs)(i.li,{children:["About 51-56% of people with cerebral palsy have epilepsy ",(0,r.jsx)(l.A,{slug:"pubmed-37769423"})," ",(0,r.jsx)(l.A,{slug:"pubmed-39596993"})]}),"\n",(0,r.jsxs)(i.li,{children:["Spastic diplegic cerebral palsy has the highest epilepsy risk ",(0,r.jsx)(l.A,{slug:"pubmed-39596993"})]}),"\n",(0,r.jsxs)(i.li,{children:["22.4% have drug-resistant epilepsy ",(0,r.jsx)(l.A,{slug:"pubmed-37769423"})]}),"\n",(0,r.jsxs)(i.li,{children:["Medication withdrawal leads to seizure recurrence in nearly half who attempt it ",(0,r.jsx)(l.A,{slug:"pubmed-37769423"})]}),"\n",(0,r.jsx)(i.li,{children:"Management requires coordination between neurologist and physiatrist"}),"\n",(0,r.jsxs)(i.li,{children:["Cerebral palsy subtype and early medical history inform epilepsy risk ",(0,r.jsx)(l.A,{slug:"pubmed-39596993"})]}),"\n"]}),"\n",(0,r.jsx)(i.hr,{}),"\n",(0,r.jsx)(i.h2,{id:"related-pages",children:"Related Pages"}),"\n",(0,r.jsxs)(i.ul,{children:["\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:(0,r.jsx)(i.a,{href:"/cerebral-palsy-knowledge-base/docs/understanding/co-occurring/secondary-conditions",children:"Secondary Conditions"})})," - Epilepsy as a secondary condition (28% prevalence)"]}),"\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:(0,r.jsx)(i.a,{href:"/cerebral-palsy-knowledge-base/docs/management/physiatrist-role",children:"Physiatrist Role"})})," - Coordinating care across specialists"]}),"\n",(0,r.jsxs)(i.li,{children:[(0,r.jsx)(i.strong,{children:(0,r.jsx)(i.a,{href:"/cerebral-palsy-knowledge-base/docs/management/spasticity",children:"Spasticity Management"})})," - Medications that may interact with seizure drugs"]}),"\n"]})]})}function p(e={}){const{wrapper:i}={...(0,t.R)(),...e.components};return i?(0,r.jsx)(i,{...e,children:(0,r.jsx)(h,{...e})}):h(e)}},8453:(e,i,s)=>{s.d(i,{R:()=>l,x:()=>a});var n=s(6540);const r={},t=n.createContext(r);function l(e){const i=n.useContext(t);return n.useMemo(function(){return"function"==typeof e?e(i):{...i,...e}},[i,e])}function a(e){let i;return i=e.disableParentContext?"function"==typeof e.components?e.components(r):e.components||r:l(e.components),n.createElement(t.Provider,{value:i},e.children)}},8609:(e,i,s)=>{s.d(i,{A:()=>a});s(6540);var n=s(7864),r=s(5548);const t={citation:"citation_ImNy",dot:"dot_MKXZ",top:"top_nqVf",mid:"mid_h4XQ",error:"error_ZChF"};var l=s(4848);function a({slug:e}){const{openOverlay:i}=(0,n.T3)(),s=r[e];if(!s)return console.warn(`Citation not found: ${e}`),(0,l.jsxs)("span",{className:t.error,children:["[Citation not found: ",e,"]"]});return(0,l.jsxs)(l.Fragment,{children:[(0,l.jsxs)("button",{className:`${t.citation} ${t[s.tier]}`,onClick:s=>{s.preventDefault(),i(e)},title:`${s.title} (${s.typeLabel})`,"data-cite":!0,children:["(",s.authorShort,", ",s.year,")",(0,l.jsx)("span",{className:t.dot,children:"\u25cf"})]}),(0,l.jsx)("br",{className:t.citeBr})]})}}}]);